A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model

Clinical and Vaccine Immunology

Volumn 18, Issue 2, 2011, Pages 187-193

  Skerry, Ciaran M ^a   Mahon, Bernard P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 5; LIVE VACCINE; PERTUSSIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNIZATION; MEMORY CELL; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PERTUSSIS; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL LOAD; BORDETELLA PERTUSSIS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PERTUSSIS VACCINE; SPLEEN; TIME FACTORS; VACCINES, ATTENUATED; WHOOPING COUGH;

EID: 79551500826     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00371-10     Document Type: Article

References (47)

1. Andreasen, C., D. Powell, and N. Carbonetti. 2009. Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PloS ONE 4:7079.
2. Baraff, L. J., W. J. Albon, and R. C. Weiss. 1983. Possible temporal association between diphtheria-tetanus toxoid-pertussis vaccination and sudden infant death syndrome. Pediatr. Infect. Dis. J. 2:7-11.
3. Barbic, J., M. Leef, D. Burns, and R. Shahin. 1997. Role of gamma interferon in natural clearance of Bordetella pertussis infection. Infect. Immun. 65:4904-4908.
4. Barnard, A., B. P. Mahon, J. Watkins, K. Redhead, and K. H. Mills. 1996. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0. Immunol. Lett. 87:372-380.
5. Boschwitz, J. S., J. W. Batanghari, H. Kedem, and D. A. Relman. 1997. Bordetella pertussis infection of human monocytes inhibits antigen-dependent CD4 T cell proliferation. J. Infect. Dis. 176:678-686.
6. Broutin, H., C. Viboud, B. T. Grenfell, M. A. Miller, and P. Rohani. 2010. Impact of vaccination and birth rate on the epidemiology of pertussis: a comparative study in 64 countries. Proc. R. Soc. B Biol. Sci. 277:3239-3245.
7. Cherry, J. D., B. P. Golden, and D. T. Karzon. 1988. Report of task force on pertussis and pertussis immunization. Pediatrics 81:939-984.
8. Cody, C. L., L. J. Baraff, J. D. Cherry, S. M. Marcy, and C. R. Manclark. 1981. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 68:650-660.
9. Crowcroft, N. S., and R. G. Pebody. 2006. Recent developments in pertussis. Lancet 367:1926-1936.
10. Dirix, V., et al. 2009. Cytokine and antibody profiles in 1-year-old children vaccinated with either acellular or whole-cell pertussis vaccine during infancy. Vaccine 27:6042-6047.
11. Dunne, A., et al. 2010. Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. J. Immunol. 185:1711-1719.
12. Esposito, S., et al. 2001. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect. Immun. 69:4516-4520.
13. Feunou, P. F., et al. 2008. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine 26:5722-5727.
14. Feunou, P. F., H. Kammoun, A.-S. Debrie, N. Mielcarek, and C. Locht. 2010. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 28:7047-7053.
15. Forsyth, K. D., et al. 2004. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin. Infect. Dis. 39:1802-1809.
16. Frey, A., J. Di Canzio, and D. Zurakowski. 1998. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods 221:35-41. (Pubitemid 29017921)
17. Gustafsson, L., H. O. Hallander, P. Olin, E. Reizenstein, and J. Storsaeter. 1996. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:349-356.
18. Ho, S. Y., et al. 2008. The highly attenuated Bordetella pertussis BPZE1 strain as a potential live vehicle for the delivery of heterologous vaccine candidates. Infect. Immun. 76:111-119.
19. Kavanagh, H., et al. 2010. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model. Clin. Exp. Allergy 40:933-941.
20. Kendrick, P. L., G. Eldering, M. K. Dixon, and J. Misner. 1947. Mouse protection tests in the study of pertussis vaccine: a comparative series using the intracerebral route for challenge. Am. J. Public Health Nations Health 37:803-810.
21. Kitamura, D., J. Roes, R. Kuhn, and K. Rajewsky. 1991. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin [mu] chain gene. Nature 350:423-426. (Pubitemid 21912244)
22. Leef, M., K. L. Elkins, J. Barbic, and R. D. Shahin. 2000. Protective immunity to Bordetella pertussis requires both B cells and Cd4+ T cells for key functions other than specific antibody production. J. Exp. Med. 191:1841-1852.
23. Mahon, B., M. Ryan, F. Griffin, and K. Mills. 1996. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect. Immun. 64:5295-5301.
24. Mahon, B. P., M. Brady, and K. H. G. Mills. 2000. Protection against Bordetella pertussis in the absence of detectable circulating antibody: implications for long-term immunity in children. J. Infect. Dis. 181:2087-2091.
25. Mahon, B. P., and K. H. G. Mills. 1999. Interferon-gamma mediated immune effector mechanisms against Bordetella pertussis. Immunol. Lett. 68: 213-217.
26. Mahon, B. P., B. J. Sheahan, F. Griffin, G. Murphy, and K. H. G. Mills. 1997. Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin μ chain genes. J. Exp. Med. 186:1843-1851.
27. Marodi, L. 2002. Down-regulation of Th1 responses in human neonates. Clin. Exp. Immunol. 128:1-2.
28. Mattoo, S., and J. D. Cherry. 2005. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18:326-382.
29. Mielcarek, N., A.-S. Debrie, S. Mahieux, and C. Locht. 2010. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin. Vaccine Immunol. 17:317-324.
30. Mielcarek, N., et al. 2006. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2:e65.
31. Mielcarek, N., et al. 1998. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat. Biotechnol. 16:454-457. (Pubitemid 28211198)
32. Mills, K. H. G., A. Barnard, J. Watkins, and K. Redhead. 1993. Cellmediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61:399-410.
33. Mills, K. H. G., M. Brady, E. Ryan, and B. P. Mahon. 1998. A respiratory challenge model for infection with Bordetella pertussis: application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity. Dev. Biol. Stand. 95:31-41.
34. Mills, K. H. G., et al. 1999. The immunology of Bordetella pertussis infection. Biologicals 27:77.
35. Mills, K. H. G., M. Ryan, E. Ryan, and B. P. Mahon. 1998. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66:594-602.
36. Olin, P., et al. 2003. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 21:2015-2021.
37. Rathore, M. H. 2003. Asymptomatic adolescents and adults may transmit pertussis infection. AAP Grand Rounds 10:25-26.
38. Redhead, K., J. Watkins, A. Barnard, and K. H. G. Mills. 1993. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect. Immun. 61:3190-3198.
39. Rowe, J., et al. 2005. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect. Immun. 73:8130-8135.
40. Ryan, M., et al. 1998. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93:1-10.
41. Skerry, C. M., et al. 2009. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice. Clin. Vaccine Immunol. 16:1344-1351.
42. Storsaeter, J., H. O. Hallander, L. Gustafsson, and P. Olin. 1998. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16:1907-1916. (Pubitemid 28473934)
43. Taranger, J., et al. 2000. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J. Infect. Dis. 181:1010-1013.
44. Vermeulen, F., et al. 2010. Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clin. Vaccine Immunol. 17:258-262.
45. Wearing, H. J., and P. Rohani. 2009. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog. 5:e1000647.
46. Wendelboe, A. M., A. Van Rie, S. Salmaso, and J. A. Englund. 2005. Duration of immunity against pertussis after natural infection or vaccination. Pediatr. Infect. Dis. J. 24(Suppl. 5):S58-S61.
47. Wortis, N., P. M. Strebel, M. Wharton, B. Bardenheier, and I. R. B. Hardy. 1996. Pertussis deaths: report of 23 cases in the United States, 1992 and 1993. Pediatrics 97:607-612. (Pubitemid 26138087)